Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study
| Autor: | Yuki Hashimoto, Kenta Murotani, Takanobu Nomura, Hidetoshi Takahashi, Yasumasa Kanai, Tomotaka Mabuchi, Shinichi Imafuku, Yayoi Tada, Satomi Kobayashi, Mariko Seishima, Mari Higashiyama, Chika Ohata, Fumikazu Yamazaki, Kei Ito, Masaru Honma, Yukari Okubo, Takuya Miyagi, Hidehisa Saeki, Tatsuyuki Kakuma |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Dermatology Antibodies Monoclonal Humanized Severity of Illness Index Biochemistry Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Japan Quality of life Rating scale Psoriasis Area and Severity Index Surveys and Questionnaires Internal medicine medicine Humans Psoriasis In real life In patient Patient Reported Outcome Measures Molecular Biology Skin Plaque psoriasis Biological Products Drug Substitution business.industry Dermatology Life Quality Index Middle Aged humanities Cross-Sectional Studies Treatment Outcome 030104 developmental biology Quality of Life Female Patient-reported outcome business |
| Zdroj: | Journal of Dermatological Science. 101:185-193 |
| ISSN: | 0923-1811 |
| DOI: | 10.1016/j.jdermsci.2021.01.002 |
| Popis: | Background Plaque psoriasis significantly affects patients’ health-related quality of life. To aid treatment decisions, not only objective assessment by physicians but also subjective assessment by patients is important. Objective To assess the significance of Dermatology Life Quality Index (DLQI) evaluation at the time of biologics introduction in clinical practice in Japanese patients with plaque psoriasis. Methods This was a single-arm, open-label, multicenter study. At baseline, Psoriasis Area and Severity Index (PASI) and DLQI scores were measured and stratified based on DLQI scores ≥6/≤5 and PASI scores ≤10/>10. Other patient-reported outcomes assessed included EQ-5D-5L, itch numerical rating scale (NRS), skin pain NRS, Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), Sleep Problem Index-II (SPI-II), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). Results Of the 73 enrolled patients, 23 had PASI scores ≤10. Those with PASI/DLQI scores >10/≥6 had a significantly higher median PASI score than those with PASI/DLQI scores >10/≤5 (p = 0.0125). Regardless of PASI scores (>10/≤10), median itch NRS and GAD-7 scores were significantly higher in patients with DLQI scores ≥6 than in those with DLQI scores ≤5 (itch NRS, p = 0.0361 and p = 0.0086, respectively; GAD-7, p = 0.0167 and p = 0.0273, respectively). Patients with PASI/DLQI scores ≤10/≥6 had significantly higher skin pain NRS (p = 0.0292) and PHQ-8 (p = 0.0255) scores and significantly lower median SPI-II scores (p = 0.0137) and TSQM-9 Effectiveness domain scores (p = 0.0178) than those with PASI/DLQI scores ≤10/≤5. Conclusion DLQI may be useful for assessing patients’ concerns that cannot be identified by PASI alone while initiating biologics or switching from other biologics in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect